Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zuzana Biesova

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
European Journal of Immunology|November 9, 2012
Aberrant antibody affinity selection in SHIP-deficient B cellsWai-Hang Leung, Tatiana Tarasenko, Zuzana Biesova, et al.
BMC Biotechnology|July 26, 2018
The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in ratsPaul R Pentel, Michael D Raleigh, Mark G LeSage, et al.
Vaccine|August 19, 2009
Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virusZuzana Biesova, Mark A Miller, Rachel Schneerson, et al.
BMC Biotechnology|August 4, 2019
Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addictionThomas Thisted, Zuzana Biesova, Celine Walmacq, et al.
Cancer Immunology Research|September 19, 2025
Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-cell ActivationThomas Thisted, F Donelson Smith, Zhi-Gang Jiang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugatesJoanna Kubler-Kielb, Fathy Majadly, Zuzana Biesova, et al.
Frontiers in Immunology|February 22, 2024
Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical modelGaëlle H Martin, Alexis Gonon, Perrine Martin-Jeantet, et al.
Nature Communications|April 4, 2024
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 responseThomas Thisted, F Donelson Smith, Arnab Mukherjee, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
European Journal of Immunology|November 9, 2012
Aberrant antibody affinity selection in SHIP-deficient B cellsWai-Hang Leung, Tatiana Tarasenko, Zuzana Biesova, et al.
BMC Biotechnology|July 26, 2018
The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in ratsPaul R Pentel, Michael D Raleigh, Mark G LeSage, et al.
Vaccine|August 19, 2009
Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virusZuzana Biesova, Mark A Miller, Rachel Schneerson, et al.
BMC Biotechnology|August 4, 2019
Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addictionThomas Thisted, Zuzana Biesova, Celine Walmacq, et al.
Cancer Immunology Research|September 19, 2025
Conditionally Active CD28xVISTA Bispecific Antibodies Promote Myeloid-Driven T-cell ActivationThomas Thisted, F Donelson Smith, Zhi-Gang Jiang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
A bicomponent Plasmodium falciparum investigational vaccine composed of protein-peptide conjugatesJoanna Kubler-Kielb, Fathy Majadly, Zuzana Biesova, et al.
Frontiers in Immunology|February 22, 2024
Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical modelGaëlle H Martin, Alexis Gonon, Perrine Martin-Jeantet, et al.
Nature Communications|April 4, 2024
VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 responseThomas Thisted, F Donelson Smith, Arnab Mukherjee, et al.
Pageof 1